ResearcherActive in the last 2 years
Marc R. Pelletier
Matched on ORCID iD 0000-0003-2860-591X; OpenAlex author ID A5075336471. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 3
- Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Ph… Co-author DOI 10.1158/1078-0432.ccr-26-0805↗
- Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
- Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. Co-author DOI 10.1053/j.gastro.2023.05.038↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Viviana Cremasco · 2 shared papers, 2023–2026 · strength 0.35
- Paper Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine ver… DOI 10.1158/1078-0432.ccr-26-0805↗
- Paper Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. DOI 10.1053/j.gastro.2023.05.038↗
- Michael Lawrence Dougan · 2 shared papers, 2023–2024 · strength 0.28
- Paper Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. DOI 10.1053/j.gastro.2023.05.038↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Victoire Cardot‐Ruffino · 2 shared papers, 2023–2024 · strength 0.28
- Paper Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. DOI 10.1053/j.gastro.2023.05.038↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Lestat R. Ali · 2 shared papers, 2023–2024 · strength 0.28
- Paper Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. DOI 10.1053/j.gastro.2023.05.038↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Stephanie K. Dougan · 2 shared papers, 2023–2024 · strength 0.28
- Paper Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. DOI 10.1053/j.gastro.2023.05.038↗
- Paper Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Ca… DOI 10.1158/2326-6066.cir-23-1073↗
- Mark Wong · 1 shared paper, 2026 · strength 0.20
- Li‐Yuan Bai · 1 shared paper, 2026 · strength 0.20
- Michèle Milella · 1 shared paper, 2026 · strength 0.20
- David Wai-Meng Tai · 1 shared paper, 2026 · strength 0.20
- Bruno Bockorny · 1 shared paper, 2026 · strength 0.20
- Gerald W. Prager · 1 shared paper, 2026 · strength 0.20
- Shivan Sivakumar · 1 shared paper, 2026 · strength 0.20
- Teresa Mercade Macarulla · 1 shared paper, 2026 · strength 0.20
- Qiang Li · 1 shared paper, 2023 · strength 0.14
- Srivatsan Raghavan · 1 shared paper, 2023 · strength 0.14
- Annan Yang · 1 shared paper, 2023 · strength 0.14
- Megan T. Hoffman · 1 shared paper, 2023 · strength 0.14
- Andrew J. Aguirre · 1 shared paper, 2023 · strength 0.14
- Harshabad Singh · 1 shared paper, 2024 · strength 0.13
- Dafna Bar‐Sagi · 1 shared paper, 2024 · strength 0.13
- Leah H. Biller · 1 shared paper, 2024 · strength 0.13
- Douglas Adam Rubinson · 1 shared paper, 2024 · strength 0.13
- Rishi Surana · 1 shared paper, 2024 · strength 0.13
- Andressa Dias Costa · 1 shared paper, 2024 · strength 0.13
- Gregor Werba · 1 shared paper, 2024 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.